Penumbra (PEN) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Business overview and product innovation

• Focused on two main business units: thrombectomy and embolization/access, with thrombectomy targeting blood clots in multiple body areas and significant patient opportunity in the U.S. and globally.

• CAVT (computer-assisted vacuum thrombectomy) technology, launched last year, is positioned as a superior, safer, and faster alternative to existing therapies, with Lightning Flash 2.0 and Lightning Bolt 7 driving growth.

• Thunderbolt for stroke is in clinical trials and expected to be introduced to the market soon.

Financial strategy and guidance

• Announced a $200 million share buyback, with $100 million already completed, reflecting strong cash resources and a focus on shareholder value.

• Guidance was reset after overestimating last year due to major product launches; now focusing on substance and performance of products.

• Optimistic about growth prospects for 2025 and 2026, with international headwinds expected to ease and new product launches supporting future performance.

Market dynamics and competitive landscape

• U.S. thrombectomy business is growing faster than main competitors, attributed to superior product performance and safety profile of Flash 2.0.

• Market penetration remains low, especially in DVT, with significant opportunity for growth through improved referral patterns and compelling clinical and economic data.

• Competition from mechanical devices is expected, but strong patent portfolio and technological advantages in CAVT provide a defensible position.